Literature DB >> 12707227

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses.

Karl-Georg Fischer, Barbara Deschler, Michael Lübbert.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707227     DOI: 10.1182/blood-2002-12-3920

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Feasibility of therapeutic plasma exchange-based combination therapy in the treatment of acquired hemophilia A: A retrospective 6 case series.

Authors:  Lin-Yue Wang; Yan Shen; Han-Qing Zeng; Ying Zhang; Shi-Feng Lou; Jian-Chuan Deng; Yun Luo
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

Review 2.  Rituximab for eradicating inhibitors in people with acquired haemophilia A.

Authors:  Tracey Remmington; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2021-08-23

3.  Successful immunoadsorption of life-threatening bleeding in factor VIII inhibitor disease, but no long-term remission with anti-CD20 treatment.

Authors:  Florian Grahammer; Karl-Georg Fischer
Journal:  BMJ Case Rep       Date:  2015-08-30

Review 4.  The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.

Authors:  Giovanni D'arena; Elvira Grandone; Matteo N D Di Minno; Pellegrino Musto; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2015-09-03       Impact factor: 3.443

5.  Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia.

Authors:  Galila Zaher; Soheir Adam
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-04-02       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.